Calcium phosphate supersaturation regulates stone formation in genetic hypercalciuric stone-forming rats

Kidney International

Volumn 57, Issue 2, 2000, Pages 550-560

  Bushinsky, David A ^a,b   Parker, Walter R ^a,b   Asplin, John R ^a,b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Calcium oxalate; Hypercalciuria; Nephrolithiasis; Renal stones

Indexed keywords

CALCIUM; CALCIUM PHOSPHATE; PHOSPHORUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM STONE; CALCIUM URINE LEVEL; CONTROLLED STUDY; DIETARY INTAKE; FEMALE; GENETIC SUSCEPTIBILITY; HYPERCALCIURIA; INBRED STRAIN; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STONE FORMATION; URINARY EXCRETION;

EID: 0033947686     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.00875.x     Document Type: Article

References (55)

1. 1. COE FL, PARKS JH: New insights into the pathophysiology and treatment of nephrolithiasis: New research venues. J Bone Miner Res 12:522-533, 1997
2. 2. ASPLIN JR, FAVUS MJ, COE FL: Nephrolithiasis, in The Kidney, edited by BRENNER BM, Philadelphia, W.B. Saunders, 1893
3. 3. BUSHINSKY DA: Renal lithiasis, in Kelly's Textbook of Medicine, edited by Kelly WF, New York, J.B. Lippincott, 1996, p 1024
4. 4. COE FL, PARKS JH, ASPLIN JR: The pathogenesis and treatment of kidney stones. N Engl J Med 327:1141-1152, 1992
5. 5. MONK RD, BUSHINSKY DA: Pathogenesis of idiopathic hypercalciuria, in Kidney Stones: Medical and Surgical Management, edited by COE F, FAVUS M, PAK C, PARKS J, PREMINGER G, New York, Raven Press, 1996, p 759
6. 6. LAERUM E, LARSEN S: Thiazide prophylaxis of urolithiasis: A double-blind study in general medical practice. Acta Med Scand 215:383-389, 1984
7. 7. ETTINGER B, CITRON JT, LIVERMORE B, DOLMAN LI: Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol 139:679-684, 1988
8. 8. BUSHINSKY DA, NEUMANN K, ASPLIN J, KRIEGER N: Alendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats. Kidney Int 55:234-243, 1999
9. 9. BUSHINSKY DA, BASHIR MA, RIORDON DR, NAKAGAWA Y, COE FL, GRYNPAS MD: Increased dietary oxalate does not increase urinary calcium oxalate saturation in hypercalciuric rats. Kidney Int 55:602-612, 1999
10. 3. J Clin Invest 101:2223-2232, 1998
11. 11. ASPLIN JR, BUSHINSKY DA, SINGHARETNAM W, RIORDON D, PARKS JH, COE FL: Relationship between supersaturation and crystal inhibition in hypercalciuric rats. Kidney Int 51:640-645, 1997
12. 12. TSURUOKA S, BUSHINSKY DA, SCHWARTZ GJ: Defective renal calcium reabsorption in genetic hypercalciuric rats. Kidney Int 51:1540-1547, 1997
13. 13. BUSHINSKY DA: Genetic hypercalciuric stone forming rats. Semin Nephrol 16:448-457, 1996
14. 3, in bone from genetic hypercalciuric rats. Am J Physiol 271 (1 Pt 1):C130-C135, 1996
15. 15. BUSHINSKY DA, NILSSON EL, NAKAGAWA Y, COE FL, GRYNPAS M: Stone formation in genetic hypercalciuric rats. Kidney Int 48:1705-1713, 1995
16. 16. BUSHINSKY DA, KIM M, SESSLER NE, NAKAGAWA Y, COE FL: Increased urinary saturation and kidney calcium content in genetic hypercalciuric rats. Kidney Int 45:58-65, 1994
17. 17. KIM M, SESSLER NE, TEMBE V, FAVUS MJ, BUSHINSKY DA: Response of genetic hypercalciuric rats to a low calcium diet. Kidney Int 43:189-196, 1993
18. 18. LIX-Q, TEMBE V, HORWITZ GM, BUSHINSKY DA, FAVUS MJ: Increased intestinal vitamin D receptor in genetic hypercalciuric rats: A cause of intestinal calcium hyperabsorption. J Clin Invest 91:661-667, 1993
19. 19. BUSHINSKY DA, FAVUS MJ: Mechanism of hypercalciuria in genetic hypercalciuric rats: Inherited defect in intestinal calcium transport. J Clin Invest 82:1585-1591, 1988
20. 20. MICHAIYLOVA V, ILKOVA P: Photometric determination of microamounts of calcium with arsenazo III. Anal Chim Acta 53:194-198, 1971
21. 21. HEINEGARD D, TIDERSTROM G: Determination of serum creatinine by a direct colorimetric method. Clin Chim Acta 43:305-310, 1973
22. 22. ICHIDA T, HINE N: Improvement of Baginski's method for phosphorus determination. Clin Chim Acta 23:378-379, 1969
23. 23. FOSSATI P, PRENCIPE L, BERTI G: Use of 3,5-dichloro-2-hydroxybenzenesulfonic acid 4-aminophenazone chromogenic system in direct enzymic assay of uric acid in serum and urine. Clin Chem 26:227-231, 1980
24. 24. ABERNATHY MH, FOWLER RT: Micellar improvement of the calmagite compleximetric measurement of magnesium in plasma. Clin Chem 28:520-522, 1982
25. 25. RATLIFF CR, HALL FF: Ammonia in plasma enzymatic procedure. Select Methods Clin Chem 9:85-90, 1982
26. 26. EISENMAN G, RUDIN DO, CASBY JU: Glass electrode for measuring sodium ion. Science 126:831-834, 1957
27. 27. STEFANAC Z, SIMON W: Highly selective cation electrode systems based on in-vitro behavior of macrotetrolides in membranes. Chimica 20:436-440, 1966
28. 28. COTLOVE E: Chloride, in Standard Methods in Clinical Chemistry, edited by SELIGSON D, New York, Academic Press, 1961, p 81
29. 29. SUGIURA M, YAMAMURA H, HIRANO K, ITO Y, SASAKI M, MORIKAWA M, INOUE M, TSUBOI M: Enzymatic determination of serum oxalate. Clin Chim Acta 105:393-399, 1980
30. 30. MOLLERING H: Citrate, in Methods of Enzymatic Analysis (vol II), edited by BERGMEYER HU, Weinhaim, Germany, Verlagsgellschaft, 1985, p 2
31. 31. MA RSW, CHAN JCM: Endogenous sulphuric acid production: A method of measurement by extrapolation. Clin Biochem 6:82-87, 1973
32. 32. FINLAYSON B: Calcium stones: Some physical and clinical aspects, in Calcium Metabolism in Renal Failure and Nephrolithiasis, edited by DAVID DS, New York, Wiley, 1977, p 337
33. 33. WERNESS PG, BROWN CM, SMITH LH, FINLAYSON B: Equil2: A basic computer program for the calculation of urinary saturation. J Urol 134:1242-1244, 1985
34. 34. BROWN CM, ACKERMANN DK, PURICH DL: EQUIL93: A tool for experimental and clinical urolithiasis. Urol Res 22:119-126, 1994
35. 44Ca labeling of bone by scanning ion microprobe. Am J Physiol (Endocrinol Metab 259(4 Pt 1):E586-E592, 1990
36. 36. BUSHINSKY DA, LECHLEIDER RJ: Mechanism of proton-induced bone calcium release: Calcium carbonate dissolution. Am J Physiol (Renal Fluid Electrolyte Physiol 253(5 Pt 2):F998-F1005, 1987
37. 37. BUSHINSKY DA, GAVRILOV K. CHABALA JM, FEATHERSTONE JDB, LEVI-SETH R: Effect of metabolic acidosis on the potassium content of bone. J Bone Miner Res 12:1664-1671, 1997
38. 38. BRESLAU NA: Calcium, magnesium, and phosphorus: Renal handling and urinary excretion, in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, edited by FAVUS M, Philadelphia, Lippincott-Raven, 1996, p 49
39. 39. MONK RD, BUSHINSKY D: Treatment of calcium, phosphorus, and magnesium disorders, in Therapy in Nephrology and Hypertension: A Companion to Brenner and Rector's the Kidney, edited by HALPERIN M, Philidelphia, W.B. Saunders, 1999, p 303
40. 40. PORTALE AA, BOOTH BE, HALLORAN BP, MORRIS RC JR: Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 73:1580-1589, 1984
41. 41. BUSHINSKY DA: Calcium, magnesium, and phosphorus: Renal handling and urinary excretion, in Primer of Metabolic Bone Diseases and Disorders of Mineral Metabolism, edited by Favus M, Philadelphia, Lippincott-Raven, 1999
42. 42. SLATOPOLSKY E, WEERTS C, LOPEZ-HILKER S, NORWOOD K, ZINK M, WINDUS D, DELMEZ J: Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 315:157-161, 1986
43. 43. BUSHINSKY DA: Disorders of calcium and phosphorus homeostasis, in Primer on Kidney Diseases, edited by GREENBERG A, San Diego, Academic Press, 1997, p 106
44. 44. FINLAYSON B, ROTH R: Appraisal of calcium oxalate solubility: In sodium chloride and sodium-calcium chloride solutions. Urology 1:142-144, 1973
45. 45. ROBERTSON WG, NORDIN BEC: Activity products in urine, in Renal Stone Research Symposium, edited by HODGEKINSON A, NORDIN BEC, London, Churchill, 1969, p 221
46. 46. DELMEZ JA, KELBER J, NORWOOD KY, GILES KS, SLATOPOLSKY E: Magnesium carbonate as a phosphorus binder: A prospective, controlled, crossover study. Kidney Int 49:163-167, 1996
47. 47. OSTER JR, HOTCHKISS JL, CARBON M, FRAMER M, VAAMONDE CA: A short duration renal acidification test using calcium chloride. Nephron 14:281-292, 1975
48. 48. PILLAY SN, ASPLIN JR, COE FL: Evidence that calgranulin is produced by kidney cells and is an inhibitor of calcium oxalate crystallization. Am J Physiol 275:F255-F261, 1998
49. 49. ASPLIN J, DEGANELLO S, NAKAGAWA YN, COE FL: Evidence that nephrocalcin and urine inhibit nucleation of calcium oxalate monohydrate crystals. Am J Physiol 261:F824-F830, 1991
50. 50. HESS B, NAKAGAWA Y, COE FL: Inhibition of calcium oxalate monohydrate crystal aggregation by urine proteins. Am J Physiol 257:F99-F106, 1989
51. 51. MANDEL NS, MANDEL GS: Urinary tract stone disease in the United States veteran population. II. Geographic analysis of variations in composition. J Urol 142:1516-1521, 1989
52. 52. SUTTON RAL, WONG NLM, DIRKS JH: Effects of metabolic acidosis and alkalosis on sodium and calcium transport in the dog kidney. Kidney Int 15:520-533, 1979
53. 53. BUSHINSKY DA: The contribution of acidosis to renal osteodystrophy. Kidney Int 47:1816-1832, 1995
54. 54. LEMANN J JR, ADAMS ND, GRAY RW: Urinary calcium excretion in human beings. N Engl J Med 301:535-541, 1979
55. 55. ALPERN RT: Trade-offs in the adaptation to acidosis. Kidney Int 47:1205-1215, 1995